Original articleGeneral thoracicIs There a Role for Pulmonary Metastasectomy With a Curative Intent in Patients With Metastatic Urinary Transitional Cell Carcinoma?
Section snippets
Material and Methods
From January 1990 to December 2005, 2,288 cases of pulmonary metastasectomy with curative intent were registered with the Metastatic Lung Tumor Study Group of Japan. We extracted 34 cases of TCC from the database. Two cases were excluded from analysis because of incomplete data. Finally, we analyzed 32 cases. The Tochigi Cancer Center Institutional Review Board approved this study, and waived the requirement of patient consent.
Clinical and pathological data included the following: patient age,
Results
Patient characteristics are shown in Table 1. The majority of the patients had solitary pulmonary metastasis (81%). Lobectomy was performed in 15 patients and limited resection in 17 patients. The primary reason for applying lobectomy was a large tumor size. The other reasons included a central location and misdiagnosis as primary lung cancer. Perioperative systemic chemotherapy was applied in 16 patients. The second pulmonary metastasectomy was conducted in 3 patients. The surgical procedures
Comment
Pulmonary metastasectomy has become a standard treatment for selected patients with several malignancies, including colorectal and renal cell carcinoma. However, pulmonary metastasectomy for patients with TCC is still controversial. The first case of pulmonary metastasectomy for TCC was reported by Orteza and colleagues in 1971 [6]. The patient was reported to have survived for more than five years. Thereafter, Cowles and colleagues [7] reported a median survival of five years in 6 patients
References (14)
- et al.
Colorectal metastasis (liver and lung)
Surg Clin North Am
(2002) - et al.
The changing role of surgery for pulmonary metastases
Ann Thorac Surg
(1979) - et al.
Transitional cell carcinoma of the bladder with pulmonary metastasis: case report on 5-year survival following resection of metastasis
J Urol
(1971) - et al.
Long-term results following thoracotomy for metastatic bladder cancer
Urology
(1982) - et al.
Surgery for pulmonary metastasis: a 20-year experience
Ann Thorac Surg
(1984) - et al.
Is there a role for surgery in the management of metastatic urothelial cancer?The M. D. Anderson experience
J Urol
(2004) - et al.
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05)
Eur Urol
(2009)
Cited by (42)
Defining Oligometastatic Bladder Cancer: A Systematic Review
2023, European Urology Open SciencePulmonary metastases in urogenital cancers: Surgical treatment and outcomes
2023, Cirugia EspanolaUtilization and outcomes of metastasectomy for patients with metastatic urothelial cancer: An analysis of the national cancer database
2022, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :One showed improved survival with solitary lung or solitary lymph node metastasis compared to other metastatic locations (81 vs 19 months).[14] Other studies, focused on reporting exclusively pulmonary metastasectomy for mUC, reported 5-year OS rates between 47%–50%.[13,16,23] A small series of 11 patients with biopsy-proven retroperitoneal mUC underwent retroperitoneal lymph node dissection after systemic chemotherapy with a reported 4-year cancer-specific survival rate of 27%.[24]
Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis
2019, European Urology FocusCitation Excerpt :After chemotherapy completion, the net benefit obtained from postchemotherapy surgery is hardly evaluable, owing to limited available data. In fact, data exist mostly from few small, retrospective, usually single-center, experiences, with just a few larger analyses [2–15]. All these studies ultimately resulted in similar findings, that is, significant survival improvement can be obtained in selected patients, in particular when cisplatin-based chemotherapy can be administered, and objective response to chemotherapy is obtained.
Lung Metastases
2019, Abeloff’s Clinical Oncology